FDA Approves Moderna's mRNA Flu Vaccine, Takeda's Narcolepsy Drug, and Replimune's Melanoma Treatment

The U.S. Food and Drug Administration (FDA) has approved Moderna's mRNA-based influenza vaccine, marking the first mRNA flu vaccine. Additionally, Takeda's orexin receptor agonist for narcolepsy type 1, the first in its class, received approval. Replimune's melanoma drug also gained FDA approval after previous rejections, signifying a cluster of novel modality approvals in vaccines and central nervous system treatments.